Back to results
US 2017/0319479 A1Published application
Enhanced stability of novel liquid compositions
AssigneePfizer Inc.
InventorsGary Robert Agisim, Robert Alan Friedline, Shivangi Akash Patel, Cesar Ivan Sertzen, Vanessa Rose Shepperson
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions of pharmaceutical agents in combination with additional pharmaceutical agents in a mixture of polyethylene glycol, polyvinylpyrrolidone, and propylene glycol and a process of making the compositions.
Claims15
1-22. (canceled)
A liquid oral pharmaceutical composition comprising:
- (i) from about 0.1% to about 20% w/v polyvinylpyrrolidone;
- (ii) from about 5% to about 70% w/v polyethylene glycol;
- (iii) from about 1% to about 30% w/v propylene glycol;
- (iv) from about 1% to 10% w/v guaifenesin;
- and
- (v) from about 0.01% to about 1.0% w/v phenylephrine;
- further comprising one or more additional pharmaceutical agent selected from the group consisting of analgesics, decongestants, expectorants, antitussives, antipyretics, anti-inflammatory agents, cough suppressants, and antihistamines;
- and wherein the composition is visually free of guaifenesin precipitation for at least 62 days at 4° C.
5 more elements
A liquid oral pharmaceutical composition comprising:
- (i) from about 0.1% to about 20% w/v polyvinylpyrrolidone;
- (ii) from about 5% to about 70% w/v polyethylene glycol;
- (iii) from about 1% to about 30% w/v propylene glycol;
- (iv) from about 1% to 10% w/v guaifenesin;
- and
- (v) from about 0.01% to about 1.0% w/v phenylephrine;
- further comprising one or more additional pharmaceutical agent selected from the group consisting of analgesics, decongestants, expectorants, antitussives, antipyretics, anti-inflammatory agents, cough suppressants, and antihistamines;
- and wherein the composition is visually free of guaifenesin precipitation for 14 days at −20° C.
5 more elements
Dependencies are inferred from the claim text.